158 related articles for article (PubMed ID: 12942106)
1. Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer.
Kloft C; Siegert W; Jaehde U
Br J Cancer; 2003 Sep; 89(5):787-94. PubMed ID: 12942106
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study.
Moeung S; Chevreau C; Broutin S; Guitton J; Lelièvre B; Ciccolini J; Massart C; Fléchon A; Delva R; Gravis G; Lotz JP; Bay JO; Gross-Goupil M; Paci A; Marsili S; Malard L; Chatelut E; Thomas F
Clin Cancer Res; 2017 Dec; 23(23):7171-7179. PubMed ID: 28928162
[No Abstract] [Full Text] [Related]
3. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
[TBL] [Abstract][Full Text] [Related]
4. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
[TBL] [Abstract][Full Text] [Related]
5. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Huitema AD; Spaander M; Mathĵt RA; Tibben MM; Holtkamp MJ; Beijnen JH; Rodenhuis S
Ann Oncol; 2002 Mar; 13(3):374-84. PubMed ID: 11996467
[TBL] [Abstract][Full Text] [Related]
6. Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors.
Chevreau C; Massard C; Flechon A; Delva R; Gravis G; Lotz JP; Bay JO; Gross-Goupil M; Fizazi K; Mourey L; Paci A; Guitton J; Thomas F; Lelièvre B; Ciccolini J; Moeung S; Gallois Y; Olivier P; Culine S; Filleron T; Chatelut E
Cancer Med; 2021 Apr; 10(7):2250-2258. PubMed ID: 33675184
[TBL] [Abstract][Full Text] [Related]
7. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetics and individual dose adjustment of carboplatin].
Chatelut E; Canal P; Bugat R
Bull Cancer; 2000 Aug; 87 Spec No():17-23. PubMed ID: 11082718
[TBL] [Abstract][Full Text] [Related]
9. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.
Schmitt A; Gladieff L; Lansiaux A; Bobin-Dubigeon C; Etienne-Grimaldi MC; Boisdron-Celle M; Serre-Debauvais F; Pinguet F; Floquet A; Billaud E; Le Guellec C; Penel N; Campone M; Largillier R; Capitain O; Fabbro M; Houede N; Medioni J; Bougnoux P; Lochon I; Chatelut E
Clin Cancer Res; 2009 May; 15(10):3633-9. PubMed ID: 19401344
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance.
Etienne MC; Leger F; Pivot X; Chatelut E; Bensadoun RJ; Guardiola E; Renée N; Magné N; Canal P; Milano G
Ann Oncol; 2003 Apr; 14(4):643-7. PubMed ID: 12649114
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
12. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.
Motzer RJ; Mazumdar M; Sheinfeld J; Bajorin DF; Macapinlac HA; Bains M; Reich L; Flombaum C; Mariani T; Tong WP; Bosl GJ
J Clin Oncol; 2000 Mar; 18(6):1173-80. PubMed ID: 10715285
[TBL] [Abstract][Full Text] [Related]
13. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review.
Morrow A; Garland C; Yang F; De Luna M; Herrington JD
J Oncol Pharm Pract; 2019 Oct; 25(7):1651-1657. PubMed ID: 30336729
[TBL] [Abstract][Full Text] [Related]
14. Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes.
Harris BDW; Phan V; Perera V; Szyc A; Galettis P; Martin JH; Walpole E; McLachlan AJ; Clarke SJ; Reuter SE; Charles KA
Clin Pharmacokinet; 2020 Aug; 59(8):1013-1026. PubMed ID: 32034726
[TBL] [Abstract][Full Text] [Related]
15. Effect of glomerular filtration rate on clearance and myelotoxicity of carboplatin in cats with tumors.
Bailey DB; Rassnick KM; Erb HN; Dykes NL; Hoopes PJ; Page RL
Am J Vet Res; 2004 Nov; 65(11):1502-7. PubMed ID: 15566088
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Calvert's formula for dosage adjustment of carboplatin in Japanese patients with hormone refractory prostate cancer.
Sato E; Yano I; Jiko M; Takahashi K; Motohashi H; Masuda S; Katsura T; Nishiyama H; Segawa T; Ito N; Kamoto T; Ogawa O; Inui K
Biol Pharm Bull; 2006 Jul; 29(7):1441-4. PubMed ID: 16819185
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
18. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
[TBL] [Abstract][Full Text] [Related]
19. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.
Donahue A; McCune JS; Faucette S; Gillenwater HH; Kowalski RJ; Socinski MA; Lindley C
Cancer Chemother Pharmacol; 2001 May; 47(5):373-9. PubMed ID: 11391850
[TBL] [Abstract][Full Text] [Related]
20. The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis.
Childs WJ; Nicholls EJ; Horwich A
Ann Oncol; 1992 Apr; 3(4):291-6. PubMed ID: 1382552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
